JPMorgan Slashes CSG to Neutral as Canadian Ammo Order Fails to Offset Margin Reset

CSG's Canadian ammunition win landed the same week its profitability story came under fresh scrutiny — and the market wasted little time picking a side. JPMorgan downgraded the stock from "Overweight" to "Neutral" and more than halved its price target, to EUR 12 from EUR 27.50, sending shares down 7.0% on the day.

The broker pointed to weakening profit prospects in medium- and large-caliber ammunition, flagging demand risks from drones, pricing pressure and expanding industry capacity. The reassessment came one day after CSG's interim report delivered a margin warning that reset expectations for the year.

Guidance Cut Puts Profitability in the Crosshairs

CSG now expects an operating EBIT margin of roughly 21% for full-year 2026, down from a previously targeted 24–25%. Management blamed lower selling prices on standard-range ammunition inventories and the drag from Land Systems as programs ramp up. Demand, meanwhile, has been shifting toward longer-range munitions.

The revenue target survived intact: CSG still guides for EUR 7.4 to 7.6 billion in 2026. But roughly EUR 300 million of sales have slipped from the third quarter into the fourth, with some deliveries pushed beyond 2026 into 2027. Working capital expectations were also revised — net working capital is now seen below 35% of revenue for 2026, versus under 20% previously.

Should investors sell immediately? Or is it worth buying CSG?

The third quarter offered a taste of the pressure: revenue fell 11.7% year on year to EUR 1,510 million. That makes the closing quarter the decisive test of whether the confirmed top-line target holds.

A Canadian Contract, but Not a Game-Changer

On the operational front, Speer — part of CSG through The Kinetic Group — reportedly secured an order to supply up to 4.2 million rounds of 9mm Luger JHP ammunition to Canada's Department of National Defence. The contract runs for up to three years.

The win adds volume, yet it does nothing to resolve the central question facing investors. A successful revenue catch-up in the fourth quarter would support confidence in the annual target. A cheaper view of the earnings picture, however, requires evidence that the pricing and ramp-up headwinds stay manageable.

CSG at a turning point? This analysis reveals what investors need to know now.

That combination — restored sales without restored margins — is what the market must now weigh. Higher volumes only strengthen the bottom line if selling conditions and launch costs allow it. Should price pressure bite harder than the revised guidance assumes, even a clean revenue recovery would deliver limited earnings support. The fourth quarter will show whether the catch-up and the margin can arrive together.

Ad

CSG Stock: New Analysis - 12 November

Fresh CSG information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated CSG analysis...